| Summary: | 博士 === 國立陽明大學 === 臨床醫學研究所 === 102 === Ovarian cancer is the most lethal cause among gynecological malignancies. Most of them are diagnosed at advanced stage. The standard treatment for advanced ovarian cancer is debulking surgery with adjuvant platinum-paclitaxel combination chemotherapy. In spite of the high response rate of initial treatment, the majority will relapse and eventually die due to the development of chemoresistance. The probability of response to retreatment with platinum depends on the platinum-free interval (PFI). It may be possible to increase response rates when re-introducing platinum by extending the PFI using non-platinum regimens. However, this hypothesis still lacks solid proof and remains to be debated.
MicroRNA is a group of small non-coding RNAs of 19-22 nucleotides in length that are broadly abundant in all multicellular eukaryotic cells. More than 2500 mature miRNAs have been identified in human. The miRNA profiling can classify stage, subtype, responsibility to treatments and prognosis in several hematopoietic and solid tumors.
Our results showed that extension of PFI could partially restore the platinum sensitivity. Six miRNAs located in two neighboring areas were identified to be correlated with the recovery of cisplatin sensitivity.
Our data implied that the ovarian cancer cells can partially retain their platinum sensitivity after platinum-free interval, even a short interval, in vitro. MicroRNA regulation may play a role in recovery of platinum-resistance after platinum-free interval. The miRNAs with significant fold-change may be a biomarker to predict the response to platinum re-introduction.
|
|---|
